Mettler-Toledo International (MTD) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 sales declined 4% year-over-year to $946.8M, with strong laboratory sales in Europe and the Americas, but continued weakness in China and Industrial segments.
Productivity and margin initiatives helped offset foreign exchange headwinds and support earnings.
Service revenue grew 5–6% in Q2, building on double-digit growth in the prior year.
Management remains focused on digitalization, process harmonization, and gaining market share despite global market softness.
Net earnings for Q2 2024 were $221.8M, up 4% year-over-year, supported by a $23M one-time tax benefit.
Financial highlights
Q2 2024 sales were $946.8M, down 2% in local currency and 4% in USD; currency reduced sales growth by 2%.
Adjusted operating profit was $284.1M, down 8% year-over-year; adjusted operating margin at 30.0%, down 130 bps.
Adjusted EPS was $9.65, down 5% year-over-year; reported EPS was $10.37, including a $1.07 one-time tax benefit.
Adjusted free cash flow YTD was $433.4M, up 13% per share year-over-year.
Operating cash flow for the first half was $447.5M, up from $420.1M year-over-year.
Outlook and guidance
Q3 2024: Local currency sales expected to grow ~1%; adjusted EPS $9.90–$10.05; 1% FX headwind.
Full year 2024: Local currency sales growth ~2%; adjusted EPS $40.20–$40.50 (prior: $39.90–$40.40); 1–2% FX headwind.
Adjusted free cash flow and share repurchases both expected at ~$850M for 2024.
Management expects sales growth to return in the second half, driven by easier comparisons and sales/marketing initiatives.
2025 will face a ~1.5% sales headwind as delayed 2023 shipments are recaptured in 2024.
Latest events from Mettler-Toledo International
- Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026 - Director elections, auditor ratification, and say-on-pay vote set for May 7, 2026.MTD
Proxy Filing18 Mar 2026 - Q4 2025 saw 8% sales and EPS growth, with a strong 2026 outlook despite market headwinds.MTD
Q4 20256 Feb 2026 - Q3 adjusted EPS up 4% on 1% sales growth; Laboratory and Service led gains amid soft markets.MTD
Q3 202415 Jan 2026 - Manufacturing flexibility, innovation, and operational programs drive growth and margin expansion.MTD
Stifel 2024 Healthcare Conference13 Jan 2026 - Innovation, digitalization, and margin expansion fuel global growth and shareholder value.MTD
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Lab and service growth offset China industrial softness; cautious 2025 outlook with service focus.MTD
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Innovation, digitalization, and service drive growth, with margin expansion and 2025 recovery expected.MTD
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance reflecting ongoing headwinds.MTD
Q4 20248 Jan 2026